Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

896.78 +9.62 (+1.08%)
Streaming Delayed Price Updated: 3:46 PM EDT, Oct 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,688,807
Open 890.51
Bid (Size) 896.52 (2)
Ask (Size) 896.86 (2)
Prev. Close 887.16
Today's Range 889.57 - 905.27
52wk Range 547.61 - 972.53
Shares Outstanding N/A
Dividend Yield 0.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotech Stocks Poised For Another Big Move In Q4
The healthcare sector can be a safe haven if volatility increases. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Performance

YTD
+51.43%
+51.43%
1 Month
-0.66%
-0.66%
3 Month
-2.31%
-2.31%
6 Month
+15.37%
+15.37%
1 Year
+56.85%
+56.85%

More News

Read More
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
Via Benzinga
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
Via The Motley Fool
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
Via Benzinga
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
Via Benzinga
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades
Via The Motley Fool
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Via Benzinga
Exposures Product Safety
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Via Benzinga
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Via Investor's Business Daily
Massive News for Hims & Hers Stock: The Truth About Today's Move
Via The Motley Fool
Eli Lilly's Options: A Look at What the Big Money is Thinking
Via Benzinga
Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000%
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
Via Benzinga
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Via Benzinga
This IPO Biotech Stock Could Be the Next Eli Lilly
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
Via Benzinga
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Via Benzinga
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
Via Benzinga
3 Momentum Trades Too Good Pass Up
Via MarketBeat
Topics ETFs
Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
Via Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
Via Benzinga
Topics Economy
Exposures Interest Rates
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.